Announced details
Drug discovery research and pharmaceutical development for pancreatic cancer
FRONTEO extracted 17 genes from approximately 20,000 human genes in about 2 days and confirmed cell proliferation-inhibitory effects for 6 of them. The University of Oklahoma also confirmed proliferation-inhibitory effects in multiple pancreatic cancer-derived cell lines.
DDAIF has already been adopted by multiple major pharmaceutical companies and is building a track record.
Joint research has been underway since July 2025. FRONTEO is responsible for identifying drug discovery target candidates and generating hypotheses concerning disease mechanisms, while the University of Oklahoma is responsible for validating their biological efficacy.
A medical research institution that is home to OU Health Stephenson Cancer Center, a National Cancer Institute (NCI)-designated cancer center. It is currently conducting more than 300 clinical trials and over 400 cancer research projects. The joint research is being conducted by the laboratory of Takebe Naoko (武部 直子), Professor of Hematology and Oncology.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
OU Health Stephenson Cancer Center, Cancer Clinical Trials
OU Health Stephenson Cancer Center, Cancer Research
National Cancer Center Japan, “Latest Cancer Statistics”
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory（DDAIF）, KIBIT (Kibit) |
| Counterparty | University of Oklahoma College of Medicine (United States) |
| Counterparty overview | A medical research institution that is home to OU Health Stephenson Cancer Center, a National Cancer Institute (NCI)-designated cancer center. It is currently conducting more than 300 clinical trials and over 400 cancer research projects. The joint research is being conducted by the laboratory of Takebe Naoko (武部 直子), Professor of Hematology and Oncology. |
| Relationship with the Company | Joint research has been underway since July 2025. FRONTEO is responsible for identifying drug discovery target candidates and generating hypotheses concerning disease mechanisms, while the University of Oklahoma is responsible for validating their biological efficacy. |
| Launch date | July 2025 (joint research commenced; actual date) |
| Applicable area | Drug discovery research and pharmaceutical development for pancreatic cancer |
| Quantitative Effects | FRONTEO extracted 17 genes from approximately 20,000 human genes in about 2 days and confirmed cell proliferation-inhibitory effects for 6 of them. The University of Oklahoma also confirmed proliferation-inhibitory effects in multiple pancreatic cancer-derived cell lines. |
| Usage history | DDAIF has already been adopted by multiple major pharmaceutical companies and is building a track record. |
| Source | OU Health Stephenson Cancer Center, Cancer Clinical Trials, OU Health Stephenson Cancer Center, Cancer Research, National Cancer Center Japan, “Latest Cancer Statistics” |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Results supporting FRONTEO's preliminary tests were obtained as a specific advance in the joint research between FRONTEO and the University of Oklahoma.